🏛️ Verified NIH Record • Updated 2026-06-03
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma (NCT07527325)
Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of California, Irvine
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Who can join: Review the eligibility criteria below.
Location: Chao Family Comprehensive Cancer Center University of California, Irvine — Orange, California
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Chao Family Comprehensive Cancer Center University of California, Irvine — Orange, California
📞 Contact the Study Coordinator
Phone: (877) 827-8839
Email: ucstudy@uci.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma (Skin)
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma — Birmingham, Alabama
- Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma — Tampa, Florida
- A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma — Toronto, Ontario
- Zr89 + PET Companion Trial — Philadelphia, Pennsylvania
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors — La Jolla, California
Explore by condition: All Melanoma (Skin) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.